The drug maker claims clinical trials of its new antiviral pill molnupiravir shows the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-19. Read full article here
The drug maker claims clinical trials of its new antiviral pill molnupiravir shows the drug halved the risk of hospitalization or death when given to high-risk people shortly after infection with COVID-19.
Read full article here
Leave a Comment
Your email address will not be published. Required fields are marked with *